DUBLIN–(BUSINESS WIRE)–The “NovoCure Ltd (NVCR) – Product Pipeline Analysis, 2025 Update” company profile has been added to ResearchAndMarkets.com’s offering.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
NovoCure Ltd (NovoCure) is an oncology company with a focus on the development and commercialization of novel delivery systems for the treatment of brain, thoracic and abdomen cancers. Its proprietary Tumor Treating Fields (TTF) technology platform uses electric fields tuned to specific frequencies to disrupt the division of solid tumor cancer cells.
The company markets TTF-based delivery systems, Optune Lua for the treatment of malignant pleural mesothelioma; and Optune Gio for the treatment of glioblastoma. The products are indicated in combination with standard chemotherapies. The company has operations in five regions, namely, United States, Germany, Japan, Greater China and Other international markets. NovoCure is headquartered in Zug, Switzerland.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Report Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company NovoCure Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
NovoCure Ltd, Recent Developments
- Dec 01, 2025: Novocure Appoints Frank Leonard as Chief Executive Officer
- Nov 12, 2025: Novocure to Participate in Jefferies Global Healthcare Conference
- Oct 15, 2025: Novocure To Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
- Oct 01, 2025: Novocure to Report Third Quarter 2025 Financial Results
- Sep 16, 2025: Novocure obtains approval for Optune Lua device in Japan to treat NSCLC
- Sep 15, 2025: Novocure’s Optune Lua Receives Approval in Japan for Treating Non-Small Cell Lung Cancer
- Aug 28, 2025: NovoCure Receives Additional Humanitarian Device Exemption For Optune Lua (NovoTTF-100L System)
- Aug 25, 2025: Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients With Newly Diagnosed Glioblastoma in Spain
- Aug 20, 2025: Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer
- Aug 19, 2025: Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients With Pancreatic Cancer
Key Topics Covered:
- NovoCure Ltd Company Overview
- NovoCure Ltd Company Snapshot
- NovoCure Ltd Pipeline Products and Ongoing Clinical Trials Overview
- NovoCure Ltd – Pipeline Analysis Overview
- Business Description
- NovoCure Ltd – Key Facts
- NovoCure Ltd – Major Products and Services
- NovoCure Ltd Pipeline Products by Development Stage
- NovoCure Ltd Ongoing Clinical Trials by Trial Status
- NovoCure Ltd Pipeline Products Overview
- Maxpoint Treatment Planning Software
- Maxpoint Treatment Planning Software Product Overview
- Next Gen Field Generator
- Next Gen Field Generator Product Overview
- NovoTTF-100M System
- NovoTTF-100M System Product Overview
- NovoTTF-100M System Clinical Trial
- NovoTTF-200A – Small Cell Lung Cancer
- NovoTTF-200A – Small Cell Lung Cancer Product Overview
- NovoTTF-200T – Advanced Non-Small Cell Lung Cancer
- NovoTTF-200T – Advanced Non-Small Cell Lung Cancer Product Overview
- NovoTTF-200T – Advanced Non-Small Cell Lung Cancer Clinical Trial
- NovoTTF-200T – Pancreatic Cancer
- NovoTTF-200T – Pancreatic Cancer Product Overview
- NovoTTF-200T – Pancreatic Cancer Clinical Trial
- Optune – Brain Metastasis
- Optune – Brain Metastasis Product Overview
- Optune – Brain Metastasis Clinical Trial
- Optune – Breast Cancer
- Optune – Breast Cancer Product Overview
- Optune – Cervical Cancer
- Optune – Cervical Cancer Product Overview
- Optune – Colorectal Carcinoma
- Optune – Colorectal Carcinoma Product Overview
- Optune – Ependymoma
- Optune – Ependymoma Product Overview
- Optune – Gliosarcoma
- Optune – Gliosarcoma Product Overview
- Optune – Liver Cancer
- Optune – Liver Cancer Product Overview
- Optune – Malignant Melanoma
- Optune – Malignant Melanoma Product Overview
- Optune – Medulloblastoma
- Optune – Medulloblastoma Product Overview
- Optune – Meningioma
- Optune – Meningioma Product Overview
- Optune – Mesothelioma
- Optune – Mesothelioma Product Overview
- Optune – Mesothelioma Clinical Trial
- Optune – Non-Small Cell Lung Cancer
- Optune – Non-Small Cell Lung Cancer Product Overview
- Optune – Ovarian Cancer
- Optune – Ovarian Cancer Product Overview
- Optune – Pancreatic Cancer
- Optune – Pancreatic Cancer Product Overview
- Optune – Pediatric Glioma
- Optune – Pediatric Glioma Product Overview
- Optune – Pediatric Glioma Clinical Trial
- Optune – Renal Adenocarcinoma
- Optune – Renal Adenocarcinoma Product Overview
- Optune – Small Cell Lung Cancer
- Optune – Small Cell Lung Cancer Product Overview
- Optune – Torso Array
- Optune – Torso Array Product Overview
- Optune – Torso Array Clinical Trial
- Optune – Urinary Transitional Cell Carcinoma
- Optune – Urinary Transitional Cell Carcinoma Product Overview
- Optune Plus Bevacizumab – Recurrent Glioblastoma
- Optune Plus Bevacizumab – Recurrent Glioblastoma Product Overview
- Optune Plus Bevacizumab – Recurrent Glioblastoma Clinical Trial
- Optune With Marizomib And Temozolomide – Glioblastoma
- Optune With Marizomib And Temozolomide – Glioblastoma Product Overview
- Optune With Pembrolizumab And Temozolomide
- Optune With Pembrolizumab And Temozolomide Product Overview
- Optune With Pembrolizumab And Temozolomide Clinical Trial
- NovoCure Ltd – Key Competitors
- NovoCure Ltd – Key Employees
- NovoCure Ltd – Key Employee Biographies
- NovoCure Ltd – Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
For more information about this company profile visit https://www.researchandmarkets.com/r/jgz6i0
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900